SCHEMBL21626790

SCHEMBL21626790

COc1cc(OC)c(F)c(Cc2n[nH]c3ncc(Br)cc23)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1B Q9Y463 3/20 0.36
FGFR1 P11362 5/20 0.34
FGFR2 P21802 3/20 0.34
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
KDR P35968 2/20 0.31
CHEK1 O14757 1/20 0.31
AURKA O14965 1/20 0.31
DAPK3 O43293 1/20 0.31
JAK2 O60674 1/20 0.31
MAP4K4 O95819 1/20 0.31
PAK4 O96013 1/20 0.31
ABL1 P00519 1/20 0.31
CSF1R P07333 1/20 0.31
RET P07949 1/20 0.31
IGF1R P08069 1/20 0.31
PDGFRA P16234 1/20 0.31
PRKACA P17612 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21626833 0.78 CYP3A4 (0.42) FGFR1CYP3A4CYP2C9CYP2C19KDR
SCHEMBL21626898 0.78 CHEK1 (0.33) DYRK1BFGFR1FGFR2KDRCHEK1
SCHEMBL21626732 0.75 FGFR3 (0.48) FGFR1FGFR2KDRABL1CSF1R
SCHEMBL14777097 0.74 MET (0.34) DYRK1BROCK1ALKBRAFMAPK1
SCHEMBL18050701 0.72 DYRK1B (0.41) DYRK1BFGFR1KDRCHEK1AURKA
SCHEMBL21626800 0.72 SIK1 (0.54) JAK2PAK4JAK3ALK
SCHEMBL23769761 0.72 FGFR3 (0.35) FGFR1FGFR2KDRJAK2IKBKE
SCHEMBL23769904 0.72 SIK1 (0.44) FGFR1FGFR2CLK2DYRK1AALK
SCHEMBL23393477 0.71 PDE1B (0.33) DYRK1B
SCHEMBL1585981 0.70 DYRK1A (0.45) DYRK1BFGFR1KDRCHEK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253571-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) 2021-08-19 US disclosed
EP-3825314-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR Medshine Discovery Inc. (CN) 2021-05-26 EP disclosed
WO-2020015744-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR 南京明德新药研发有限公司 2020-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253571-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR MET, FGFR1, FGFR2 DYRK1B 484/4885FGFR1 2/4885FGFR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.